


PHARMACEUTICAL 2018



VERTEX PHARMACEUTICALS INC MA Rank 39 of 349







PHARMACEUTICAL 2018

Rank 39 of 349



VERTEX PHARMACEUTICALS INC MA



The relative strengths and weaknesses of VERTEX PHARMACEUTICALS INC MA are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of VERTEX PHARMACEUTICALS INC MA compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 425% points. The greatest weakness of VERTEX PHARMACEUTICALS INC MA is the variable Assets, Current, reducing the Economic Capital Ratio by 21% points.

The company's Economic Capital Ratio, given in the ranking table, is 115%, being 392% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	2,648,963
Cost of Goods Sold	0
Intangible Assets	50,384
Liabilities, Current	807,260
Liabilities, Non-Current	26,048
Other Assets	57,230
Other Compr. Net Income	139,104
Other Expenses	437,381
Other Liabilities	670,400
Other Net Income	-138,932
Property and Equipment	789,437
Research and Development	1,324,625
Revenues	2,488,652
Selling, General and Administrative Expense	496,079

Output Variable	Value in 1000 USD
Assets	3,546,014
Liabilities	1,503,708
Expenses	2,258,085
Stockholders Equity	2,042,306
Net Income	91,635
Comprehensive Net Income	161,187
Economic Capital Ratio	115%